Skip to main content

Table 3 FEV1 change from baseline and FF/VI vs placebo treatment difference following cessation of treatment

From: Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

Day relative to last dose Time point Adjusted Mean FEV1 Difference (FF/VI vs Placebo) 95% CI of the difference
n FF/VI 100/25 mcg n Placebo
0 AM 27 0.44 27 0.18 0.26 (0.16, 0.36)
  PM 27 0.44 27 0.07 0.38 (0.28, 0.48)
1 AM 27 0.38 27 0.02 0.36 (0.26, 0.46)
  PM 27 0.41 27 0.15 0.26 (0.16, 0.36)
2 AM 27 0.37 27 0.03 0.34 (0.24, 0.44)
  PM 27 0.41 27 0.16 0.24 (0.14, 0.34)
3 AM 27 0.31 27 0.05 0.26 (0.16, 0.36)
  PM 27 0.36 27 0.18 0.18 (0.08, 0.28)
4 AM 27 0.29 27 0.05 0.24 (0.14, 0.34)
  PM 27 0.34 26 0.18 0.17 (0.07, 0.27)
5 AM 27 0.24 26 0.17 0.07 (−0.03, 0.17)
7a AM 27 0.13 24 0.09 0.04 (−0.06, 0.14)
21a AM 27 0.06 27 0.03 0.03 (−0.07, 0.13)
  1. Legend: Summary of repeated measures statistical analysis of change from baseline forced expiratory volume in one second (FEV1), in litres, after cessation of repeat dose of treatment. Day 1 to Day 5 data was collected whilst subjects were in-patients. aDay 7 and Day 21 measurements were taken during outpatient visits